RecruitingNCT06183762

A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer

Real-World Treatment Patterns and Effectiveness of Targeted and Systemic Therapy in Patients With Advanced Lung Cancer Carrying MET Mutation-Positive

Sponsor

Hunan Province Tumor Hospital

Enrollment

200 participants

Start Date

Jan 1, 2020

Study Type

OBSERVATIONAL

Conditions

Advanced Lung Cancer

Summary

This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data will be collected in a forward-looking manner. This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data from patients on prior treatment will be collected retrospectively, and data from patients who will be treated later and included in the study will be collected in a prospective manner. The criteria for retrospective collection were consistent with those for prospective collection. Eligible patients will be enrolled after NGS analysis of tumor tissue and informed consent has been obtained. Information required for the study will be collected (every 3 months).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a real-world observational study that tracks how patients with advanced non-small cell lung cancer (NSCLC) harboring MET mutations are actually being treated in clinical practice — and how well those treatments work. MET is a protein that, when mutated, can drive cancer growth, and newer targeted drugs have been developed to block it. **You may be eligible if...** - You are 18 or older - You have confirmed advanced or metastatic NSCLC (Stage IIIB, IIIC, or IV) - Your tumor has been tested by next-generation sequencing (NGS) and shows a MET mutation - You have provided informed consent **You may NOT be eligible if...** - Your lung cancer has not been tested for MET mutations, or the test was negative - Your cancer is not NSCLC or is at an earlier, potentially resectable stage - You have not consented to participate Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.